share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  12/09 19:07

牛牛AI助理已提取核心訊息

Conduit Pharmaceuticals Inc. has received notice from the United States Securities and Exchange Commission (SEC) regarding the effectiveness of its S-3 Form. The Form S-3, with file number 333-283449, became effective on December 6, 2024, at 4:30 P.M.This development signifies that the company's registration statement has been approved by the SEC, potentially allowing Conduit Pharmaceuticals to offer and sell securities to the public. The S-3 Form is commonly used by public companies to register securities for future public offerings, providing the company with increased flexibility in accessing capital markets.
Conduit Pharmaceuticals Inc. has received notice from the United States Securities and Exchange Commission (SEC) regarding the effectiveness of its S-3 Form. The Form S-3, with file number 333-283449, became effective on December 6, 2024, at 4:30 P.M.This development signifies that the company's registration statement has been approved by the SEC, potentially allowing Conduit Pharmaceuticals to offer and sell securities to the public. The S-3 Form is commonly used by public companies to register securities for future public offerings, providing the company with increased flexibility in accessing capital markets.
Conduit Pharmaceuticals Inc. 已收到美國證券交易委員會(SEC)關於其 S-3 表格有效性的通知。文件編號爲 333-283449 的 S-3 表格於 2024 年 12 月 6 日下午 4:30 生效。這一發展標誌着公司的註冊聲明已獲得 SEC 批准,可能允許 Conduit Pharmaceuticals 向公衆提供和賣出證券。S-3 表格通常由上市公司用來註冊未來的公開發行證券,爲公司在獲取資本市場的資金提供了更大的靈活性。
Conduit Pharmaceuticals Inc. 已收到美國證券交易委員會(SEC)關於其 S-3 表格有效性的通知。文件編號爲 333-283449 的 S-3 表格於 2024 年 12 月 6 日下午 4:30 生效。這一發展標誌着公司的註冊聲明已獲得 SEC 批准,可能允許 Conduit Pharmaceuticals 向公衆提供和賣出證券。S-3 表格通常由上市公司用來註冊未來的公開發行證券,爲公司在獲取資本市場的資金提供了更大的靈活性。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。